ANKIB1 Inhibitors
ANKIB1 inhibitors represent a class of chemical compounds specifically designed to target and impede the activity of ANKIB1, a protein encoded by the ANKIB1 gene, which is implicated in various cellular functions including intracellular signaling and protein-protein interactions. These inhibitors work by binding to the protein at critical functional domains, thereby altering its conformation and preventing it from participating in its normal biological processes. The inhibitory action of these compounds is highly specific, focusing on the unique structural features and active sites of ANKIB1 to ensure minimal off-target effects. By doing so, ANKIB1 inhibitors can effectively dampen the protein's activity without influencing the broader cellular pathways in which it operates.
The design of ANKIB1 inhibitors is grounded in a deep understanding of the protein's role and the molecular mechanisms it engages in within the cell. The inhibitors are characterized by their ability to disrupt the interactions between ANKIB1 and other proteins or molecules, which may be critical for the propagation of signaling cascades that ANKIB1 influences. They can also impact the protein's ability to bind to specific nucleic acids or other intracellular components it may normally interact with. In essence, ANKIB1 inhibitors are tailored to ensure that the protein's functional attributes are neutralized, leading to a decrease in the biochemical pathways that are regulated or facilitated by ANKIB1 without altering other cellular functions. The precision of these inhibitors reflects a sophisticated approach to targeting a specific protein of interest, paving the way for a profound understanding of the protein's role within the cell and the broader biological context in which it operates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting kinase activity, it disrupts phosphorylation events crucial for many signaling pathways, indirectly leading to the functional inhibition of ANKIB1, which may rely on phosphorylation for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. PI3K signaling is essential for many cellular processes. Inhibition of PI3K can lead to a decrease in AKT phosphorylation, which in turn might affect ANKIB1 function if ANKIB1 is part of the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that blocks the mTORC1 pathway, which is involved in cell growth and proliferation. By inhibiting mTORC1, rapamycin may reduce the cellular events in which ANKIB1 participates, such as growth factor signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, it may interfere with signaling pathways involved in stress responses that could be regulating ANKIB1 activity or expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that prevents the activation of MAPK/ERK kinase. This disruption can lead to the inhibition of the MAPK/ERK pathway, potentially affecting ANKIB1 if it is regulated by this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of regulatory proteins within the cell, potentially leading to an accumulation of proteins that negatively regulate ANKIB1 function. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a potent RAF kinase inhibitor which could downregulate the MAPK pathway. This could result in altered signaling events that may inhibit ANKIB1 if it is influenced by MAPK pathway activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002 and may similarly affect ANKIB1 through the PI3K/AKT pathway by inhibiting downstream signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the regulation of apoptosis and cell proliferation. Inhibition of JNK could affect ANKIB1 if there is regulatory interplay between JNK signaling and ANKIB1. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
GF109203X is a protein kinase C inhibitor. Since PKC is involved in a multitude of signaling pathways, its inhibition could also impact ANKIB1 activity if ANKIB1 is regulated by PKC-dependent signaling. | ||||||